Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 273-281

  Pithavala, Yazdi K ^a   Tong, Warren ^a,b   Mount, Janessa ^a   Rahavendran, Sadayappan V ^a   Garrett, May ^a   Hee, Brian ^a   Selaru, Paulina ^a   Sarapa, Nenad ^a,c   Klamerus, Karen J ^a  

^a PFIZER INC   (United States)

^b ALLERGAN INC   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Axitinib; Corrected QT; CYP3A; Drug interaction; Ketoconazole; Pharmacokinetics; Simcyp ; TaqMan allelic discrimination

Indexed keywords

AXITINIB; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A; KETOCONAZOLE; PLACEBO;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; GASTRITIS; HEADACHE; HUMAN; HUMAN EXPERIMENT; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANGIOGENESIS INHIBITORS; AREA UNDER CURVE; BIOTRANSFORMATION; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; IMIDAZOLES; INDAZOLES; KETOCONAZOLE; MALE; MIDDLE AGED; PHENOTYPE; SINGLE-BLIND METHOD;

EID: 84856533799     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9511-6     Document Type: Article

References (12)

1. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272-7283. doi:10.1158/ 1078-0432.CCR-08-0652
2. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokinerefractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 8:975-984. doi:10.1016/S1470-2045(07)70285-1 (Pubitemid 47629888)
3. Fruehauf J, Lutzky J, McDermott D, Brown CK, Pithavala Y, Bycott P, Shalinsky D, Liau KF, Niethammer A, Rixe O (2008) Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study. J Clin Oncol (Meeting Abstracts) 26: 9006.
4. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468. doi:10.1200/JCO.2008.21.7034
5. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J (2009) Efficacy and safety of axitinib in patients with advanced nonsmall- cell lung cancer: Results from a phase II study. J Clin Oncol 27:3836-3841. doi:10.1200/JCO.2008.20.8355
6. Cohen EE, Rosen LS, Vokes EE, KiesMS, Forastiere AA,Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713. doi:10.1200/JCO.2007.15.9566
7. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483
8. Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ (2010) Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 65: 563-570. doi:10.1007/s00280-009-1065-y
9. Zientek M, Kang P, Jiang Y, Neul D, Friewald S, Smith BJ (2010) In vitro kinetic characterization of axitinib metabolism to estimate the clinical implications of genetic polymorphisms. International Society for the Study of Xenobiotics-Workshop on Genetic Polymorphisms in Drug Disposition; Indianapolis, IN, April 11-13, 2010
10. Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K, Yamada H (2006) Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: Dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34:1277-1282 (Pubitemid 44079866)
11. Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, Hamilton M (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: Computer-based simulation (Sim- CYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 64:31-41. doi:10.1007/s00228-007- 0396-z
12. Garrett M, Houk BE, Myrand SP, Hee B, Mota J, Pithavala YK (2007) A population pharmacokinetic (PK) analysis to evaluate the potential effect of the UGT1A1*28 genotype on the PK of AG- 013736, an anti-angiogenic agent. Clin Pharmacol Ther 81:S21-S21